Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Earth Science Tech, Inc. operates in the specialty pharmaceutical and nutraceutical space, focusing on cannabinoid-based products and dietary supplements. The company has demonstrated explosive revenue growth (177% YoY) from a small base, with exceptionally high margins (73% gross margin) and strong ROE (74%), suggesting a capital-light model with minimal infrastructure requirements. The stock has experienced significant volatility with a -36.6% decline over six months despite strong fundamental growth metrics.
The company generates revenue through direct sales of specialty pharmaceutical products, primarily cannabinoid-derived formulations, and nutraceutical supplements. The 73.4% gross margin indicates either high-value proprietary formulations, favorable supply agreements, or direct-to-consumer distribution that eliminates intermediary costs. With minimal debt (0.03 D/E) and exceptional ROE (74%), the business model appears asset-light, likely relying on contract manufacturing or third-party production facilities. The 177% revenue growth suggests either market share gains in an emerging category, new product launches, or expansion into new distribution channels. Pricing power appears strong given the ability to maintain 10.4% operating margins while scaling rapidly.
Regulatory developments affecting cannabinoid-based pharmaceuticals and CBD product classifications
New product launches or clinical trial results for proprietary formulations
Distribution agreements with major retailers or pharmacy chains
Quarterly revenue growth rates and gross margin sustainability as the company scales
Changes in consumer acceptance and market penetration of cannabinoid-based wellness products
Evolving FDA regulatory framework for cannabinoid-based products creates approval uncertainty and potential reclassification risks that could restrict sales channels or require costly reformulations
Market saturation risk as CBD and cannabinoid wellness products proliferate, with major pharmaceutical and consumer health companies entering the category with superior distribution and brand recognition
Dependence on third-party contract manufacturers creates supply chain vulnerability and limits control over quality and production costs
Large pharmaceutical companies (e.g., Jazz Pharmaceuticals with Epidiolex) and consumer health giants (e.g., Charlotte's Web, CV Sciences) possess superior capital, distribution networks, and regulatory expertise
Commoditization of CBD products as ingredient costs decline and differentiation becomes difficult without significant R&D investment in proprietary formulations or clinical validation
E-commerce and direct-to-consumer brands can rapidly gain market share with lower customer acquisition costs through digital marketing
Near-zero reported revenue ($0.0B TTM) despite 177% growth suggests extremely small absolute revenue base, creating going-concern questions about cash runway and need for dilutive equity raises
Zero reported operating cash flow and free cash flow despite positive net margins indicates potential working capital strain, timing mismatches, or non-cash revenue recognition
Micro-cap market capitalization creates liquidity risk for investors and vulnerability to delisting if the company cannot maintain exchange listing requirements
moderate - Specialty pharmaceuticals and wellness products exhibit mixed cyclicality. Prescription-based pharmaceutical products are relatively recession-resistant, but discretionary nutraceutical and CBD wellness products are more sensitive to consumer spending patterns. The 177% growth rate suggests the company is in a market penetration phase where category expansion may override cyclical pressures. However, as a small-cap company with limited brand recognition, consumer discretionary spending cuts during recessions could disproportionately impact sales growth. The high gross margins provide cushion to maintain profitability through downturns.
Rising interest rates create multiple headwinds: (1) Higher discount rates compress valuation multiples for high-growth, unprofitable or marginally profitable companies, particularly impacting the 1.1x P/S multiple; (2) Consumer financing costs increase, potentially reducing discretionary spending on wellness products; (3) The company's minimal debt (0.03 D/E) means direct financing cost impact is negligible, but future capital raises become more expensive. The 8.2x EV/EBITDA valuation is vulnerable to multiple compression in rising rate environments, especially for micro-cap healthcare names.
Minimal direct credit exposure given the 0.03 debt-to-equity ratio and 1.34 current ratio indicating adequate liquidity. The company is not dependent on credit markets for operations. However, as a micro-cap growth company, access to equity capital markets for future growth funding could be constrained during credit stress periods when risk appetite declines. Customers are likely individual consumers or small retailers, minimizing accounts receivable credit risk compared to B2B models.
momentum/speculative - The combination of explosive 300%+ net income growth, micro-cap size, and -36.6% six-month decline attracts speculative traders and momentum investors seeking high-risk, high-reward opportunities in emerging healthcare categories. The cannabinoid pharmaceutical angle appeals to thematic investors focused on cannabis sector exposure. Institutional investors are likely absent given the $0.0B market cap and liquidity constraints. The 9.5% FCF yield appears attractive but is contradicted by $0.0B reported FCF, suggesting data quality issues that deter fundamental value investors.
high - Micro-cap healthcare stocks in emerging regulatory categories exhibit extreme volatility. The -36.6% six-month decline despite strong fundamentals indicates sentiment-driven price action disconnected from operating performance. Thin trading volumes, regulatory headline risk, and speculative investor base create conditions for 20-30% single-day moves on news. The stock likely trades more on sector sentiment around cannabis/CBD products than company-specific fundamentals.
